NEW YORK (TheStreet) -- Shares of BioCryst Pharmaceuticals (BCRX) fell Thursday on more than twice their usual volume after the Birmingham, Ala.-based drug developer was hit with a downgrade by Bank of America-Merrill Lynch.
The firm mainly cited a weakening outlook for Peramivir, the company's proposed flu treatment, for the lowering of its rating on the shares to underperform from neutral. It also cut its 12-month price target on the stock by 37.5% to $5 from $8.
"Given weak worldwide flu trends and FDA's rejection of BioCryst's peramivir trial approach, we now expect a 1-year launch delay to 2013 and more modest flu incidence expectations," Bank of America-Merrill Lynch said in a note to clients. "The key phase 3 study (301) has been slow to enroll patients in the southern hemisphere and will likely require next year's flu season to satisfy enrollment requirements."
The stock was down 6.4% to $4.81 shortly after the closing bell. Volume of around 977,000 compared to the issue's trailing three-month daily average of roughly 377,000. Year-to-date, the shares have fallen around 20%, but they had rallied some since plumbing a 52-week low of $4.43 on August 25, hitting an intraday high of $5.69 on Sept. 14.Bank of America-Merrill Lynch also expressed restrained optimism about the clinical progress that BioCryst recently reported on a potential treatment for gout, where its BCX4208 drug showed promise in combination with allopurinol. "We have modest expectations for this drug without visibility regarding the risk of lymphocyte impact to patients," the firm said, adding that it will be looking to see the results of the monotherapy trial of BCX4208 at the American College of Rheumatology meeting in November. The firm added that a gout drug being developed by Ardea Biosciences (RDEA) actually posted stronger results in combination with allopurinol, making it "a more compelling therapeutic approach." Another drug company recently made headlines by getting approval for a gout drug, Savient Pharmaceuticals (SVNT), whose stock is up more than 60% year-to-date.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV